Background: chronic endogenous depression in youth has a number of features associated with their severe atypia, work and social maladjustment, deterioration in the quality of life, high risk of suicidal and self-injurious behavior, difficulties in choosing therapy, difficulty in diagnosis and nosological evaluation. Until now, no special research has been done on chronic endogenous depression among young people of this age.Purpose of research: to identify psychopathological features and dynamics of endogenous depression developed in youth, to work out a clinical typology. Patients: 62 young patients (16–25 years old) were clinically and psychopathologically examined, who were first admitted to FSBSI MHRC, within the period of 2017 to 2020 suffering from chronic endogenous depression state for more than two years. Clinically significant somatic, neurological, and mental pathology defined the criteria for exclusion.Methods: for the research the clinical-psychopathological and psychometric methods were used. The patients were examined by the psychometric method upon admission to the hospital and at the stage of reduction of psychopathological disorders upon discharge: the HDRS, SANS and SOPS scales included.Results and conclusion: the clinical picture of youth chronic endogenous depression is characterized by pronounced polymorphism, atypia, erosion of the thymic component, and the dominance of negative affectivity. Based on the analysis of psychopathological characteristics of endogenous depression in youth, two typological varieties were identified: unitary depressions (type I) and supplementary depressions (type II). Among the type II depressions, 2 subtypes were distinguished: with neurosis-like disorders and with psychopathic-like disorders.
Objective: Establishing a link between the structure and severity of psychopathological symptoms and the level of functioning in patients at risk of schizophrenia. Material and Methods: The study examined 38 patients with a depressive episode with attenuated positive symptoms (APS) from the risk group of schizophrenia hospitalized in 2011-2015. The follow-up was 7.3 ± 1.7 years. At the time of the examination, all patients were in remission. HDRS (Hamilton Depression Rating Scale), SOPS (Scale of Prodromal Symptoms) and (SANS) Scale for Assessment of Negative Symptoms were used. Statistical analysis was carried out using the Statistica 12 program. Results: At the time of the survey, 21.1% of the cases were diagnosed as schizophrenic (F25 and F20 according to ICD-10), 28.9 % as affective (F34.0, F31.3, F31.7 and F33.4), 13.2 % as personal disorders (F60.1, F60.a, F3.8 per cent) and 36,8 % as schizotypal disorders (F21.3, F21.4, F21.5, F21.8). Social performance on the PSP scale of 13.2 % was rated as high (100-81 points), 28.9 % and 31.6 % as average (80-61 and 60-41 points respectively) and 26.3 % as low (less than 40 points). The strongest correlations (p˂0.05) are found between total scores on the SOPS scale, negative SOPS scores, total SANS score and PSP score (- 0.854, - 0.876, - 0.812 respectively), subscale of negative SOPS symptoms and socially beneficial PSP activity (-0.831) subscale of apathy-anhedonia SANS and social relations PSP (0,801). Discussion: A high level of social functioning is possible provided there is a complete reduction of the prodromal and depressive symptoms, at medium levels, functioning is determined primarily by increasing negative symptoms, especially the domain of avolition - apathy, and low levels are formed by persistent APS, increasing symptoms of disorganization and negative symptoms. Conclusion: The study showed that the outcome of the first depressive episode with the risk symptoms of schizophrenia is generally characterized by some degree of decline in social functioning, which cannot be considered as a phenomenon in its own right, on the contrary, it’s a derivative of psychopathological symptoms.
Introduction Currently, there are many studies on the effect of the duration of an untreated psychosis on the further course of the disease. In terms of the duration of the untreated illness (DUI) in depression, such studies are significantly less. However, the delay in starting treatment for depression has also been found to have a negative impact on subsequent treatment. Objective To determine the effect of DUI on the severity of symptoms during the first depressive episode in non-psychotic mental disorders in youth and the degree of their reduction during treatment. Material and methods Diagnosed 52 male in-patients (16-25 years) who were first hospitalized for a depression in non-psychotic mental disorders affective disorders (F31, F32, F33, F34), personality disorders (F60) and schizotypal disorder (F21). The duration of the DUI was 35.817.0 months. The patients were divided into two groups: 1 group (59.6%, n=31) with the DUI lasting more than 36 months, 2 group (40.4%, n=21) with the DUI lasting less than 36 months. HDRS, SOPS and SANS were used. The examination was conducted twice at the time of the patients admission to hospital and before discharge. Statistical analysis was carried out with Statistica 12. Results There was no difference in the severity of the clinical symptoms upon admission. However, there were some differences in the residual depressive symptoms on the HDRS scale (p=0.019), negative symptoms on the SOPS (p=0.069), symptoms of disorganization on the SOPS (p=0.091), the total score of the SOPS (p=0.069), negative symptoms Alogia on the SANS (p=0.083), Anhedonia Asociality of the SANS (p=0.058) and the total score on the SANS (p=0.093) at the time of discharge in the patients of 1 group. Conclusion The DUI affects the reduction of depressive, negative and disorganized symptoms of youth depression in non-psychotic mental disorders.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.